Canada - English - Health Canada

eugia pharma inc. - pemetrexed (pemetrexed disodium) - powder for solution - 1000mg - pemetrexed (pemetrexed disodium) 1000mg

Israel - English - Ministry of Health

k.s.kim international (sk- pharma) ltd., israel - pemetrexed as disodium hemipentahydrate - powder for concentrate for solution for infusion - pemetrexed as disodium hemipentahydrate 500 mg - pemetrexed - pemetrexed s.k. in combination with cisplatin is indicated for the treatment of patients with malignant pleural mesothelioma whose disease is unresectable or who are otherwise not candidates for curatible surgery. pemetrexed s.k. in combination with cisplatin is indicated for the first line treatment of patients with locally advanced or metastatic non-small cell lung cancer other than predominantly squamous cell histology. pemetrexed s.k. is indicated as monotherapy for the second line treatment of patients with locally advanced or metastatic non-small cell lung cancer other than predominantly squamous cell histology. pemetrexed s.k. is indicated as monotherapy for the maintenance treatment of locally advanced or metastatic non-small cell lung cancer other than predominantly squamous cell histology in patients whose disease has not progressed immediately following platinum-based chemotherapy.

New Zealand - English - Medsafe (Medicines Safety Authority)

viatris limited - pemetrexed disodium hemipentahydrate 604.12mg equivalent to pemetrexed 500 mg - powder for infusion - 500 mg - active: pemetrexed disodium hemipentahydrate 604.12mg equivalent to pemetrexed 500 mg excipient: hydrochloric acid mannitol sodium hydroxide - malignant pleural mesothelioma pemetrexed infusion is indicated for the treatment of patients with malignant pleural mesothelioma in combination with cisplatin.

New Zealand - English - Medsafe (Medicines Safety Authority)

viatris limited - pemetrexed disodium hemipentahydrate 604.12mg equivalent to pemetrexed 500 mg - powder for infusion - 500 mg - active: pemetrexed disodium hemipentahydrate 604.12mg equivalent to pemetrexed 500 mg excipient: hydrochloric acid mannitol sodium hydroxide - malignant pleural mesothelioma pemetrexed infusion is indicated for the treatment of patients with malignant pleural mesothelioma in combination with cisplatin.

Australia - English - Department of Health (Therapeutic Goods Administration)

arrotex pharmaceuticals pty ltd - pemetrexed disodium hemipentahydrate, quantity: 120.8 mg (equivalent: pemetrexed, qty 100 mg) - injection, powder for - excipient ingredients: mannitol; hydrochloric acid; sodium hydroxide - malignant pleural mesothelioma,pemetrexed, in combination with cisplatin, is indicated for the treatment of patients with malignant pleural mesothelioma.,non-small cell lung cancer (nsclc),pemetrexed, in combination with cisplatin, is indicated for initial treatment of patients with locally advanced or metastatic nsclc other than predominantly squamous cell histology.,pemetrexed, as monotherapy, is indicated for the treatment of patients with locally advanced or metastatic nsclc other than predominantly squamous cell histology after prior platinum-based chemotherapy.

Australia - English - Department of Health (Therapeutic Goods Administration)

arrotex pharmaceuticals pty ltd - pemetrexed disodium hemipentahydrate, quantity: 120.8 mg (equivalent: pemetrexed, qty 100 mg) - injection, powder for - excipient ingredients: sodium hydroxide; mannitol; hydrochloric acid - malignant pleural mesothelioma,pemetrexed, in combination with cisplatin, is indicated for the treatment of patients with malignant pleural mesothelioma.,non-small cell lung cancer (nsclc),pemetrexed, in combination with cisplatin, is indicated for initial treatment of patients with locally advanced or metastatic nsclc other than predominantly squamous cell histology.,pemetrexed, as monotherapy, is indicated for the treatment of patients with locally advanced or metastatic nsclc other than predominantly squamous cell histology after prior platinum-based chemotherapy.

Australia - English - Department of Health (Therapeutic Goods Administration)

dr reddys laboratories australia pty ltd - pemetrexed disodium, quantity: 551.4 mg (equivalent: pemetrexed, qty 500 mg) - injection, powder for - excipient ingredients: hydrochloric acid; sodium hydroxide; mannitol; water for injections - malignant pleural mesothelioma:,pemtrex, in combination with cisplatin, is indicated for the treatment of patients with malignant,pleural mesothelioma.,non-small cell lung cancer:,pemtrex in combination with cisplatin is indicated for initial treatment of patients with locally,advanced or metastatic non-small cell lung cancer other than predominantly squamous cell histology.,pemtrex as monotherapy is indicated for the treatment of patients with locally advanced or,metastatic non-small cell lung cancer other than predominantly squamous cell histology after prior,platinum-based chemotherapy.

Australia - English - Department of Health (Therapeutic Goods Administration)

dr reddys laboratories australia pty ltd - pemetrexed disodium, quantity: 551.4 mg (equivalent: pemetrexed, qty 500 mg) - injection, powder for - excipient ingredients: water for injections; sodium hydroxide; hydrochloric acid; mannitol - malignant pleural mesothelioma:,pelimta, in combination with cisplatin, is indicated for the treatment of patients with malignant,pleural mesothelioma.,non-small cell lung cancer:,pelimta in combination with cisplatin is indicated for initial treatment of patients with locally,advanced or metastatic non-small cell lung cancer other than predominantly squamous cell histology.,pelimta as monotherapy is indicated for the treatment of patients with locally advanced or,metastatic non-small cell lung cancer other than predominantly squamous cell histology after prior,platinum-based chemotherapy.

European Union - English - EMA (European Medicines Agency)

medac gesellschaft für klinische spezialpräparate mbh - pemetrexed - carcinoma, non-small-cell lung; mesothelioma - folic acid analogues, antineoplastic agents - malignant pleural mesothelioma pemetrexed medac in combination with cisplatin is indicated for the treatment of chemotherapy naïve patients with unresectable malignant pleural mesothelioma. non-small cell lung cancer pemetrexed medac in combination with cisplatin is indicated for the first line treatment of patients with locally advanced or metastatic non-small cell lung cancer other than predominantly squamous cell histology. pemetrexed medac is indicated as monotherapy for the maintenance treatment of locally advanced or metastatic non-small cell lung cancer other than predominantly squamous cell histology in patients whose disease has not progressed immediately following platinum-based chemotherapy. pemetrexed medac is indicated as monotherapy for the second line treatment of patients with locally advanced or metastatic non-small cell lung cancer other than predominantly squamous cell histology.,

European Union - English - EMA (European Medicines Agency)

sandoz gmbh - pemetrexed disodium hemipentahydrate - carcinoma, non-small-cell lung; mesothelioma - antineoplastic agents - malignant pleural mesothelioma pemetrexed sandoz in combination with cisplatin is indicated for the treatment of chemotherapy naive patients with unresectable malignant pleural mesothelioma. non-small cell lung cancer pemetrexed sandoz in combination with cisplatin is indicated for the first-line treatment of patients with locally advanced or metastatic non-small cell lung cancer other than predominantly squamous cell histology. pemetrexed sandoz is indicated as monotherapy for the maintenance treatment of locally advanced or metastatic non-small cell lung cancer other than predominantly squamous cell histology in patients whose disease has not progressed immediately following platinum-based chemotherapy. pemetrexed sandoz is indicated as monotherapy for the second-line treatment of patients with locally advanced or metastatic non-small cell lung cancer other than predominantly squamous cell histology.,